Generate a tailored SOP for Dr. Phillip Kearney. Improve your application with a focused, well-structured draft.
Phillip Kearney is an Adjunct Associate Professor at the University of New South Wales, holding an MBA from the University of Sydney and a PhD in genetics from Monash University. He completed postdoctoral studies at Imperial College London, focusing on mapping the human Y chromosome, and later worked on mapping the X chromosome at Murdoch Institute in Melbourne. Returning to Sydney, he led the Haematology Research Laboratory for 12 years, concentrating on ribozyme gene therapy approaches for treating Chronic Myeloid Leukaemia. In 2000, he moved to ActiveBiotech AB in Sweden, where he headed preclinical oncology studies and later became Head of Biology at Santaris Pharma, a company focused on antisense-mediated RNA knockdown therapies. In 2007, he joined Merck Sharp & Dohme, where he scouted innovative research and development opportunities across the Asia Pacific region. He has led significant licensing deals, including the Vaxxas patch technology for vaccine delivery and various academic partnerships totaling $2 billion. After 15 years at MSD, he transitioned to executive roles at Axelia Oncology and Amaroq Therapeutics.
University of New South Wales • Sydney, Australia
Engaged in research and teaching within the field of genetics and biotechnology.
Santaris Pharma • Sweden
Led research initiatives focused on antisense-mediated RNA therapy.
Merck Sharp & Dohme • Sydney, Australia
Identified and facilitated research partnerships and licensing deals across the Asia Pacific.
Includes Business Intelligence, Enterprise Systems, and Cybersecurity Management streams.